Researchers reported a spine-stimulating implant might aid neurodegenerative diseases like spinal muscle atrophy.
Brett P. Monia, the Chief Executive Officer of Ionis Pharmaceuticals Inc. (NASDAQ:IONS), sold 38,843 shares of the company's common stock on February 4, according to a recent SEC filing. The sale ...
Patrick R. O'Neil, Executive Vice President, Chief Legal Officer & General Counsel of Ionis Pharmaceuticals Inc. (NASDAQ:IONS), recently sold 6,165 shares of the company's common stock. The shares ...
Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
In surveys, parents of children with SMA and healthcare professionals in Sweden note the many ways the pandemic affected ...
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback